Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05001828 · ClinicalTrials.gov registry record · Phase 1
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
A Phase 1 study of Acute Myeloid Leukemia, Adult, sponsored by Polaris Group.
- Active
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 3
- Study locations
NCT05001828 is a Phase 1 study of Acute Myeloid Leukemia, Adult that is active but no longer recruiting, run by Polaris Group. The registered enrollment target is 38 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT05001828, a Phase 1 study of Acute Myeloid Leukemia, Adult, is active but no longer recruiting, sponsored by Polaris Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 3
- Study locations
Study Summary
Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine for treatment of subjects with previously treated or untreated with high risk factor acute myeloid leukemia (AML). Venetoclax and azacitidine are front-line therapy for such patients, and ADI-PEG 20 will be added to this regimen in a phase IA/B study.
Conditions Studied
Interventions
- DRUG ADI-PEG 20
Study Locations (3)
Florida
- Sylvester Comprehensive Cancer Center - Miami
North Carolina
- Levine Cancer Institute - Charlotte
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-04-05 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05001828
The ClinicalTrials.gov registry entry for NCT05001828 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Polaris Group, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myeloid Leukemia, Adult appearing as the primary indexed condition, and to 1 intervention - of which ADI-PEG 20 is the first listed.
NCT05001828 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT05001828 about?
NCT05001828 is a clinical study titled "Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia". Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine for treatment of subjects with previously treated or untreated with high risk factor acute myeloid leukemia (AML). Venetoclax and azacitidine are front-line therapy for such patients, and ADI-PEG 20 will be ad...
What is the current status of trial NCT05001828?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2022-04-05. Estimated completion is 2026-12.
What conditions does trial NCT05001828 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Adult.
What interventions are being tested in trial NCT05001828?
The interventions under investigation include: ADI-PEG 20 (DRUG).
Who is sponsoring clinical trial NCT05001828?
This trial is sponsored by Polaris Group, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05001828 being conducted?
This trial has 3 study locations across Florida, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.